News & Events

Exchange Bulletin

Thallion Pharmaceuticals Inc. To Trade On TSX Venture Exchange

December 11, 2012

THALLION PHARMACEUTICALS INC. ("TLN")
BULLETIN TYPE: New Listing-Shares
BULLETIN DATE: December 11, 2012
TSX Venture Tier 2 Company

The common shares of Thallion Pharmaceuticals Inc. (the "Company") will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below.

Listing Date:At the close of business (5:01 p.m. EST) on Tuesday, December 11,
2012.

Commence Date:The common shares will commence trading on TSX Venture Exchange at the opening Wednesday, December 12, 2012.

Please note that the common shares of the Company (Symbol: TLN) will be delisted from Toronto Stock Exchange at the close of business on Tuesday, December 11, 2012, and will be listed on TSX Venture Exchange at the same time.

Corporate Jurisdiction:Canada

Capitalization:Unlimited common shares without nominal value of which 32,194,566 common shares are issued and outstanding

Escrowed Shares:None

Transfer Agent:Computershare Trust Company of Canada (Montreal and Toronto)
Trading Symbol: TLN
CUSIP Number: 88327P105

The Company is classified as a "Research and Development in the Physical, Engineering and Life Sciences" issuer (NAICS Number: 541710). For further information, please refer to the Company's continuous disclosure information available on SEDAR.

Company Contact:Mr. Michael Singer
Chief Financial Officer
Company Address:1375 TransCanada Highway, Suite 200, Dorval, Quebec H9P 2W8

Company Phone Number:(514) 940-3600
Company Fax Number:(514) 940-3621
Company Email Address: info@thallion.com
Company Web site: www.thallion.com